To sum up, intranasal administration of rh‐B4galt1 was protective following cerebral ischemia–reperfusion, with 0.18 μg/kg dose showing the greatest function and being selected for follow‐up experiments. The gene discussed is B4GALT1; the disease is Cerebral ischemia.